Produit
AGENTS IA
APPLICATIONS DE L'IA
AUTRES
Solutions
SECTEURS D'ACTIVITÉ
Tarification
Ressources
EXPLORER
ENGAGER
ASSISTANCE ET SERVICES
À propos
Plateforme PatSnap Eureka
Mandataires en propriété intellectuelle
Agents pour l'ingénierie
Agents pour les sciences de la vie
Agents pour matériaux
Analytique
Intelligence IPSynapse
Renseignement biopharmaceutiqueBiographie
Recherche et analyse de séquences biologiquesChimique
Recherche et analyse de structures chimiquesEureka AI à l'intérieur
Services professionnels
Témoignages clients
Blog
Rapport mondial sur l'innovation
Glossaire
Newsroom
Webinaires et formations
Frontière
Communauté d'utilisateurs
Confiance et sécurité
PatentBench
LLM
Centre d'aide
Carrières
Accès à plus de 2 000 000 000 points de données structurées dans les domaines des brevets, des sciences, des litiges et des technologies.
Innovez 75 % plus vite à un coût réduit de 25 %.
Cloud ou sur site pour une confidentialité et un contrôle maximaux
Reconnu par plus de 18 000 innovateurs à travers le monde
Pour l'utiliser, cliquez sur le bouton de vérification dans l'e-mail que nous avons envoyé à [email protected].
Cela contribue à sécuriser votre compte.
Vous devriez le recevoir sous peu. N'oubliez pas de vérifier votre dossier spam.
Unlock professional features and history
Already have an account? Log In
To start using PatSnap Eureka, click the verification button in the email we sent to .
This helps keep your account secure.
Haven't received it? Check your spam folder.
Série soigneusement sélectionnée offrant des informations précieuses aux professionnels de l'innovation.
Article | Rapport How to reduce plasma-induced damage during reactive ion etching of low-k dielectric layers in advanced logic nodes — mechanisms, process strategies, and ALE.
Article | Rapport Explore the 2026 cellulose acetate membrane technology landscape: nanocomposite filtration, hemodialysis biocompatibility, antimicrobial packaging, and IP strategy.
Article | Rapport How to reduce plasma-induced damage during reactive ion etching of low-k dielectrics in sub-7 nm logic nodes — chemistry, pulsed RF, ALE, and passivation strategies.
Article | Rapport RNA silencing, TTR stabilizers, CRISPR editing, and monoclonal antibodies are reshaping the ATTR amyloidosis pipeline beyond patisiran. Explore the IP landscape.
Article | Rapport VRFB electrolyte technology landscape 2026: concentration enhancement, additive science, hybrid redox couples, and non-aqueous systems mapped across 40 years of patents.
Article | Rapport How interface trap density at gate dielectric boundaries drives threshold voltage instability in GaN power HEMTs — mechanisms, measurement, and mitigation strategies.
Article | Rapport How interface trap density at gate dielectric boundaries drives threshold voltage instability in GaN power HEMTs — mechanisms, measurements, and mitigation strategies.
Article | Rapport Gene therapy, cardiac regeneration, and structural defect correction approaches in the CHD drug pipeline — AAV vectors, RNA therapeutics, organoids, and more.
Article | Rapport Patent landscape analysis of transparent conductive electrode (TCE) technology in 2026: metal mesh, ITO alternatives, carbon-based, and stretchable architectures mapped across 5 material families.
Article | Rapport mTOR inhibitors, AAV gene therapy, ganaxolone, and ASO strategies shaping the TSC drug pipeline. A patent-intelligence analysis by PatSnap Insights.
Article | Rapport How SOD1 ASOs, TDP-43 splice-switch oligonucleotides, anti-TDP-43 antibodies, and neurofilament biomarkers are reshaping the ALS drug pipeline. Patent intelligence analysis.
Article | Rapport How does microfluidic chip-based cell sorting compare to FACS for CAR-T therapy? Patent data reveals a 100x sensitivity gain and closed-system sterility advantages.
Article | Rapport Analyse the progressive MS drug pipeline: BTK inhibitors, remyelination strategies, and neuroprotection approaches. Patent intelligence from PatSnap Eureka.
Article | Rapport How XAI mechanisms help clinical decision support systems meet EU AI Act transparency, auditability, and compliance requirements. Patent analysis from 8 key filings.
Article | Rapport VMAT2 inhibitors dominate the tardive dyskinesia drug pipeline. Explore patent landscape analysis of valbenazine, deutetrabenazine, PDE7/PDE10 inhibitors, and emerging gene therapy approaches.